ABBV

With the Federal Reserve likely to maintain or raise interest rates through the end of 2026, dividend stocks like AbbVie are positioned to perform well. AbbVie, a pharmaceutical company with over 50 years of dividend increases, offers resilience in a high-rate environment due to its strong balance sheet, fixed-rate debt, and non-rate-sensitive business model.

AbbVie's neuroscience revenues are projected to reach $3.29 billion in Q3 2026, representing approximately 16% year-over-year growth. Key contributors include established drugs Vraylar ($1.08B) and Botox Therapeutic ($1.07B), along with newer products like Vyalev ($283M) and the recently FDA-approved Juvmo. The company faces competition from Biogen and Johnson & Johnson in the neuroscience market.

Zacks Market Edge podcast episode #503 features five stock picks for investors seeking opportunities amid market volatility. The selections span growth stocks (Palantir, Palo Alto Networks), value plays (BP), consistent performers (Visa), and pharmaceuticals (AbbVie), offering diverse investment strategies across different market conditions.